We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

Boston Scientific to Acquire EndoChoice

By HospiMedica International staff writers
Posted on 28 Sep 2016
Boston Scientific Corporation (Marlborough, MA, USA) has agreed to acquire EndoChoice Holdings, Inc. More...
(Alpharetta, GA, USA), which will become part of its endoscopy business after completion of the transaction.

Boston Scientific develops, manufactures and markets medical devices used in a range of interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

EndoChoice focuses on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, as well as devices, infection control products and pathology services for gastrointestinal specialists. The company’s portfolio includes single-use devices, such as resection and retrieval devices, needles, graspers and infection control kits.

Both the companies have entered into a definitive agreement under which Boston Scientific will launch a tender offer for all of EndoChoice’s outstanding shares at a cash price of USD 8 per share. The total equity value of the deal is approximately USD 210 million and the transaction is expected to close in the fourth quarter.

"The addition of EndoChoice products and services to our portfolio supports our strategy to provide comprehensive solutions to gastroenterology caregivers and the patients they serve," said Art Butcher, senior vice president and president, Boston Scientific, endoscopy. "We expect the acquisition to expand our leadership into new categories in the endoscopy market, and to drive strong, continued growth of our endoscopy business."

Mark Gilreath, founder and chief executive officer, EndoChoice, said, "The combination of our broad portfolio of products and services for the gastroenterology physician, with the complementary products and large global infrastructure of the Boston Scientific endoscopy business, creates an enhanced growth platform for both businesses, and delivers immediate value for our shareholders."

Related Links:
Boston Scientific
EndoChoice

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Patient Monitoring System
AlarmSense
Digital Radiography System (Ceiling Free)
Digix CF Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: 123RF

Existing Cardiovascular Risk Calculators Predict Several Common Cancers

Cardiovascular risk calculators are embedded in primary and secondary care to estimate 10‑year risk of heart attack or stroke from factors such as age, body mass index, and smoking. Many of these same... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.